The cost of biologics for psoriasis is increasing

Drugs in Context

Volumn 3, Issue , 2014, Pages

  Cheng, Judy ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Adalimumab; Cost analysis; Etanercept; Psoriasis; Ustekinumab

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; ETANERCEPT; USTEKINUMAB;

ARTICLE; BIOLOGICAL THERAPY; DRUG COST; HUMAN; MAINTENANCE THERAPY; PRESCRIPTION; PSORIASIS;

EID: 84928920454     PISSN: 17451981     EISSN: 17404398     Source Type: Journal    
DOI: 10.7573/dic.212266     Document Type: Article

References (36)

1. Hankin CS, Feldman SR, Szczotka A, Stinger RC, Fish L, Hankin DL. A cost comparison of treatments of moderate to severe psoriasis. Drug Beneft Trends 2005;17(5):200-14.
2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9(2):136-9. http://dx.doi.org/10.1046/j.1087-0 024. 20 03.09102.x
3. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007;57(6):957-62. http://dx.doi.org/10.1016/j.jaad.2007.06.042
4. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137(3):280-4.
5. Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis-best use of biologics. Expert Rev Clin Immunol 2014;10(2):269-79. http://dx.doi.org/10.1586/1744666X.2014.873701
6. Bhosle MJ, Feldman SR, Camacho FT, Timothy Whitmire J, Nahata MC, Balkrishnan R. Medication adherence and health care costs associated with biologics in Medicaidenrolled patients with psoriasis. J Dermatol Treat 2006;17(5):294-301. http://dx.doi.org/10.1080/09546630600954594
7. Fonia A, Jackson K, Lereun C, Grant DM, Barker JN, Smith CH. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol 2010;163(4):807-16. http://dx.doi.org/10.1111/j.1365-2133.2010.09944.x
8. Driessen R, Bisschops L, Adang E, Evers AW, Van De Kerkhof PC, De Jong EM. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 2010;162(6):1324-99.
9. Miller DW, Feldman SR. Cost-effectiveness of moderateto-severe psoriasis treatment. Expert Opin Pharmacother 2006;7(2):157-67. http://dx.doi.org/10.1517/14656566.7.2.157
10. Pearce DJ, Nelson AA, Fleischer Jr AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatol Treat 2006;17(1):29-37. http://dx.doi.org/10.1080/09546630500504754
11. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efciency. Expert Opin Pharmacother 2011;12(13):2041-54. http://dx.doi.org/10.1517/14656566.2011.590475
12. Red Book Drug Topics, 2014. Available at: http://www.micromedexsolutions.com/micromedex2/librarian. [Last accessed: 6 November 2014].
13. Sterry W, Ortonne JP, Kirkham B et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147. http://dx.doi.org/10.1136/bmj.c147
14. FDA. Humira (adalimumab) label - FDA, 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/125057s0276lbl.pdf. [Last accessed: 6 November 2014].
15. FDA. Stelara FDA Label, 2009. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/20 09/125261l bl.pdf. [Last accessed: 6 November 2014].
16. Amgen. 2013 Annual Report and 10-K, 2013. Available at: http://investors.amgen. com/phoenix.zhtml?c=61656&p= irol-reportsannual. [Last accessed: 6 November 2014].
17. AbbVie. 2013 Annual Report on Form 10-K and 2014 Proxy Statement, 2013. Available at: http://www.abbvieinvestor.com/phoenix.zhtml?c= 251551&p=irol-reportsannual. [Last accessed: 6 November 2014].
18. Johnson J. Sales and Earnings, 2014. Available at: http://www.investor.jnj.com/sales-earnings.cfm. [Last accessed: 6 November 2014].
19. Bureau of Labor Statistics. Consumer Price Index - All Urban Consumers: Medical Care, 2014. Available at: http://data.bls.gov/timeseries/CUUR0000SAM?output-view=pct-12mths. [Last accessed: 6 November 2014].
20. Bureau Labor Statistics. CPI Detailed Report: Data for March 2014. Available at: http://www.bls.gov/cpi/cpid1403.pdf. [Last accessed: 6 November 2014].
21. Nelson AA, Pearce DJ, Fleischer Jr AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective effcacy measures assessed over a 12-week treatment period. J Am Acad Dermatol 2008;58(1):125-35. http://dx.doi.org/10.1016/j.jaad.2007.09.018
22. Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol 2010;146(1):46-54. http://dx.doi.org/10.1001/archdermatol.2009.319
23. Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol 2013;14(4):315-26. http://dx.doi.org/10.1007/s40257-013-0030-z
24. Schabert V, Korn J, Bilir P, De Koven M, Harrison DJ, Joseph G. Cost per treated patient for biologics across adult indications using claims data. Value Health 2013;16(3):A220. http://dx.doi.org/10.1016/j.jval.2013.03.1118
25. Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatol Treat 2011;22(3):138-43. http://dx.doi.org/10.3109/09546634.2010.542800
26. Hankin CS, Bhatia ND, Goldenberg G et al. A comparison of the clinical effectiveness and cost-effectiveness of treatments for moderate to severe psoriasis. Drug Benefit Trends 2010;22(1):17-27.
27. AMCP Task Force on Drug Payment Methodologies. AMCP guide to pharmacuetical payment methods, 2013 Update (Version 3.0). Available at: http://www.amcp.org/Tertiary.aspx?id=16359. [Last accessed: 28 November 2014].
28. Tufts Center for the Study of Drug Development. Total cost to develop a new prescription drug, including cost of postapproval research, is $897 million, according to Tufts Center for the Study of Drug Development. Available at: http://www.businesswire.com/news/home/20030513005057/en/Total-Cost-Develop-Prescription-Drug-Including-Cost-.U1l39OZdWkQ. [Last accessed: 6 November 2014].
29. National Clinical Guideline Centre. Psoriasis: assessment and management of psoriasis. 2012. Available at: https://www.nice.org.uk/guidance/cg153. [Last accessed: 6 November 2014].
30. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation consensus conference. J Am Acad Dermatol 2009;60(5):824-37. http://dx.doi.org/10.1016/j.jaad.2008.11.906
31. Pathirana D, Ormerod A, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(Suppl 2):1-70.
32. Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatol Treat 2011;22(2):65-74. http://dx.doi.org/10.3109/09546630903551258
33. Chi C-C, Wang SH. Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle. Biomed Res Int 2014;862851. http://dx.doi.org/10.1155/2014/862851
34. Menter A, Baker T. Cost-efficacy analysis of biological treatments in psoriasis: an 18-month assessment. J Med Econ 2005;8(14):139-46. http://dx.doi.org/10.3111/200508135146
35. Villacorta R, Hay JW, Messali A. Cost efectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics 2013;31(9):823-39. http://dx.doi.org/10.1007/s40273-013-0078-x
36. Blackstone E, Fuhr Jr J P. Innovation and competition: will biosimilars succeed? Biotechnol Healthc 2012;9(1):24-7.